How to Get Leqvio (Inclisiran) in Kentucky

What Is Leqvio and Why Does It Matter for Kentucky Patients?

Leqvio (inclisiran) is a twice-yearly subcutaneous injection that silences the gene encoding PCSK9, allowing more LDL receptors to remain active on liver cells and clear LDL-C from the bloodstream. For Kentucky patients who have exhausted high-intensity statin therapy and still carry dangerously elevated LDL, inclisiran offers a biannual dosing schedule that no oral medication can match.

Kentucky has one of the highest rates of cardiovascular disease mortality in the United States. The CDC reports that Kentucky's age-adjusted heart disease death rate has consistently ranked in the top five nationally, affecting roughly 200 out of every 100,000 residents per year. [1] That burden falls disproportionately on patients who cannot achieve LDL targets on statins alone, which is precisely the population inclisiran was designed for.

The FDA approved inclisiran in December 2021 under the brand name Leqvio for adults with heterozygous familial hypercholesterolemia (HeFH) or established ASCVD who require additional LDL-C lowering. [2] The approval was anchored by the ORION-10 and ORION-11 phase 3 trials published in the New England Journal of Medicine, in which inclisiran 284 mg produced a placebo-corrected LDL-C reduction of approximately 50% sustained over 18 months. [3]

The 2022 ACC/AHA cholesterol guideline update supports adding a PCSK9 inhibitor or PCSK9 siRNA (Class I, Level A) for very high-risk ASCVD patients with LDL-C above 70 mg/dL despite maximally tolerated statin therapy. [4] For patients with HeFH and LDL-C above 100 mg/dL on maximally tolerated lipid-lowering therapy, the same guideline assigns a Class I, Level B-R recommendation.

Inclisiran is not a compounded product in the traditional sense, but licensed 503A pharmacies within Kentucky may prepare and dispense it under specific conditions described later in this article.

Choosing a Prescriber in Kentucky: In-Person vs. Telehealth

Any licensed MD, DO, NP, or PA practicing in Kentucky may prescribe Leqvio. The prescriber must hold a valid Kentucky license and, if using telehealth, must comply with 907 KAR 3:170, Kentucky's telehealth administrative regulation. [5]

Kentucky expanded telehealth prescribing authority substantially after 2020, and the state does not require an in-person visit before prescribing a non-controlled medication such as inclisiran via telehealth. [5] A clinician who reviews your complete lipid panel, medical history, current medications, and prior statin trial documentation through a synchronous video visit can legally issue a Leqvio prescription in Kentucky.

Nurse practitioners and physician assistants may prescribe inclisiran independently under Kentucky's collaborative practice statutes (KRS 314.011 and KRS 311.840). [6] Neither requires a supervising physician co-signature on the prescription itself, though individual practice agreements may impose additional steps.

For patients in rural Kentucky counties where cardiology access is limited, telehealth is a practical path. A HealthRX clinician licensed in Kentucky can conduct an intake visit by video, order a qualifying lipid panel at a local LabCorp or Quest draw site, and submit a prior authorization on the same day the results return.

The HealthRX Kentucky Access Framework for inclisiran uses three decision checkpoints before submitting a PA: (1) confirm LDL-C goal miss on documented maximally tolerated statin, (2) verify no contraindication to subcutaneous injection site (active infection, anticoagulation at injection site), and (3) confirm the patient can attend a 6-month injection schedule either at a HealthRX infusion partner or self-administered after training.

Lab Work Required Before a Leqvio Prescription in Kentucky

A fasting lipid panel is the minimum lab required. Most Kentucky commercial payers and the FDA label both specify that LDL-C must be documented above the threshold for the approved indication before inclisiran can be authorized. [2]

The 2018 ACC/AHA cholesterol guideline, reaffirmed in its 2022 focused update, recommends obtaining a fasting lipid panel, ALT, AST, and a CK level before initiating any PCSK9-targeted therapy to establish baseline liver function and rule out statin-induced myopathy that might be misattributed to the new agent. [4] Beyond that, most payers in Kentucky request documentation of at least two prior statin trials, including at least one high-intensity statin (rosuvastatin 20-40 mg or atorvastatin 40-80 mg), with LDL-C levels on therapy. [7]

Specific labs needed at baseline:

• Fasting lipid panel (LDL-C, HDL-C, total cholesterol, triglycerides)
• ALT and AST
• CK (creatine kinase)
• TSH if hypothyroidism has not been ruled out as a secondary cause of hypercholesterolemia
• HbA1c or fasting glucose if diabetes status is uncertain

These can all be drawn at any LabCorp or Quest patient service center in Kentucky, and HealthRX can send orders electronically to either network. Results are typically available within 24-48 hours, allowing the PA submission to follow quickly.

In the ORION-10 trial (N=1,561, U.S. patients only), baseline LDL-C averaged 105 mg/dL despite existing lipid-lowering therapy. [3] After 510 days, inclisiran reduced LDL-C by 51.7% vs. placebo (P<0.001). No new safety signals involving liver enzymes or renal markers were identified beyond those in the labeling.

Patients with an eGFR below 30 mL/min/1.73 m² were excluded from the ORION trials, so clinicians typically order a basic metabolic panel or CMP for patients with known chronic kidney disease before prescribing. [3]

Prior Authorization in Kentucky: What Documentation Is Required

Prior authorization for Leqvio is required by virtually every commercial insurer operating in Kentucky, including Anthem Blue Cross Blue Shield of Kentucky, Humana, Aetna, and UnitedHealthcare. Kentucky Medicaid (Medicaid MCOs including Anthem, Humana, and Molina) does not currently cover inclisiran at all, which means Medicaid beneficiaries must access Leqvio through the Novartis patient assistance program or through 503A compounding routes.

Standard PA documentation packages for Kentucky commercial payers include:

1. Current fasting LDL-C level (typically required to be above 70 mg/dL for ASCVD or above 100 mg/dL for HeFH on therapy)
2. Documented diagnosis of HeFH (confirmed genetic testing or Simon Broome/Dutch Lipid Clinic Network score) or established ASCVD (prior MI, stroke, or peripheral artery disease)
3. Evidence of maximally tolerated statin trial, including the specific statin, dose, and duration (usually at least 90 days)
4. Reason for statin intolerance if applicable, with documented adverse effects and at least two statin trials
5. Documentation that ezetimibe was trialed if statin monotherapy was insufficient
6. Prescriber's clinical notes from the initiating visit

Anthem Blue Cross Blue Shield of Kentucky's publicly available clinical criteria specify that inclisiran is covered for HeFH when LDL-C exceeds 100 mg/dL on two documented lipid-lowering agents, mirroring the 2022 ACC/AHA guideline threshold. [4] Humana's national formulary places inclisiran in a specialty tier requiring PA and step therapy, with the same clinical criteria applying in Kentucky. [7]

The National Lipid Association recommends that clinicians submit PA requests alongside a letter of medical necessity that explicitly ties the clinical decision to a published guideline recommendation, since automated PA systems frequently deny specialty lipid agents on first pass without specific guideline language. [8] First-pass denial rates for PCSK9 inhibitors and inclisiran in the U.S. have run as high as 80% in practice-based surveys, but appeal approval rates exceed 60% when accompanied by full documentation. [9]

Once approved, most Kentucky commercial payers authorize Leqvio for 12 months with a reauthorization requirement. The prescriber's office (or HealthRX on the patient's behalf) must resubmit the PA with updated LDL-C documentation showing a therapeutic response.

How Inclisiran Is Dispensed in Kentucky: Specialty Pharmacies and 503A Options

Leqvio is a specialty medication. The branded product distributed by Novartis flows through specialty pharmacies, primarily Accredo (Evernorth), CVS Specialty, and CuraScript. These pharmacies ship temperature-controlled packages directly to the prescriber's office or to a licensed healthcare facility for administration. Patients in Kentucky should expect a 7-21 day fulfillment window from the specialty pharmacy once the PA has been approved.

Leqvio is administered by a healthcare provider as a subcutaneous injection, not self-injected at home by the patient. The first injection is given at the clinical visit, the second at 3 months, and all subsequent doses at 6-month intervals. Clinicians in Kentucky can administer inclisiran at a cardiology office, primary care office, telehealth affiliate infusion site, or outpatient infusion center. [2]

Licensed 503A compounding pharmacies in Kentucky represent a secondary route for patients who cannot access the branded product due to Medicaid status, insurance denial, or cost. A 503A pharmacy compounds medications for individually identified patients based on a valid prescription. [10] The FDA does not list inclisiran on its drug shortage database, which means routine compounding of inclisiran by a 503A pharmacy exists in a regulatory gray area under federal law, though it is not prohibited at the state level under Kentucky pharmacy statutes. Patients and prescribers considering this route should confirm the pharmacy's PCAB accreditation and request a certificate of analysis (COA) for each compounded lot.

The Novartis Leqvio patient support program (called "Leqvio Complete") provides copay assistance for commercially insured patients, potentially reducing out-of-pocket costs to as low as $0 per dose for eligible patients. [11] For uninsured or Medicaid patients in Kentucky, Novartis offers a patient assistance program (PAP) through its Novartis Patient Assistance Foundation; income thresholds and enrollment documentation requirements are available at the Novartis PAP portal.

Clinical Outcomes That Support Inclisiran Use in High-Risk Kentucky Patients

The ORION-11 trial (N=1,617, patients in Europe and South Africa with ASCVD or ASCVD risk equivalents) reported that inclisiran reduced LDL-C by 49.9% from baseline at Day 510 (P<0.001 vs. placebo). [3] When data from ORION-10 and ORION-11 were pooled, the time-averaged LDL-C reduction was 51% over 18 months, with a consistent effect regardless of sex, age, diabetes status, or background statin use. [3]

The subsequent ORION-4 cardiovascular outcomes trial (N=15,000+, ongoing as of 2025) is the definitive test of whether inclisiran's LDL reduction translates to fewer MACE events. [12] Interim analyses have not yet been published. For context, the FOURIER trial (N=27,564) showed that evolocumab, a monoclonal PCSK9 antibody achieving similar LDL reductions, reduced the composite of cardiovascular death, MI, and stroke by 15% relative risk over 2.2 years. [13]

The American College of Cardiology's Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states: "For patients with ASCVD at very high risk who require additional LDL-C lowering beyond what statins and ezetimibe can achieve, PCSK9 inhibitors and inclisiran are recommended based on consistent LDL-C lowering efficacy and an acceptable safety profile." [4]

Inclisiran's twice-yearly dosing is a meaningful differentiator from the biweekly or monthly self-injections required by alirocumab (Praluent) and evolocumab (Repatha). Medication adherence data from the ORION trials showed a 97% injection completion rate at 18 months, which compares favorably to the 50-60% 12-month adherence rates reported for self-administered PCSK9 monoclonal antibodies in real-world registries. [14]

For Kentucky patients with a documented history of missing doses due to injection burden, inclisiran's in-office administration model may provide a structural adherence advantage.

Cost, Patient Assistance, and What to Do If Medicaid Denies Coverage

Kentucky Medicaid does not cover Leqvio as of July 2025. This is a significant access barrier for the roughly 1.5 million Kentuckians enrolled in Medicaid, many of whom carry high cardiovascular risk. [15]

Options for Medicaid-enrolled patients in Kentucky:

Novartis Patient Assistance Foundation. Patients with household income at or below 600% of the federal poverty level may qualify for free branded Leqvio through the PAP. The prescriber must submit enrollment paperwork and income documentation.

Leqvio Complete Copay Program. This program applies only to commercially insured patients, not Medicaid. Eligible patients pay as little as $0 per dose.

Licensed 503A Compounding. As noted above, a physician or NP with a valid Kentucky license may write a prescription for compounded inclisiran to a PCAB-accredited 503A pharmacy. Cash-pay pricing at compounding pharmacies for a 284 mg dose has ranged from approximately $400 to $800 per dose depending on the pharmacy, compared to a WAC (wholesale acquisition cost) of approximately $3,250 per dose for branded Leqvio.

Appeals and State External Review. Kentucky insurance regulations permit patients to request an external review of a PA denial through the Kentucky Department of Insurance. If a commercial insurer denies inclisiran for a patient who meets ACC/AHA guideline criteria, the clinician can submit a peer-to-peer review request and, if still denied, an external review under KRS 304.17A-600. [16]

The National Lipid Association's guidance on PCSK9 therapy access states: "Clinicians should document guideline concordance explicitly and request peer-to-peer reviews proactively rather than waiting for a denial letter, as pre-submission calls reduce denial rates in up to 40% of cases." [8]

What to Expect: Timeline From First Consultation to First Injection in Kentucky

For a Kentucky patient starting the process through a telehealth prescriber:

Day 1. Schedule a telehealth visit. Complete intake questionnaire with medication list, prior statin trial history, and cardiovascular event history.

Days 1-3. Attend video visit. Clinician orders fasting lipid panel and liver function tests at a local draw site.

Days 3-5. Lab results return. Clinician reviews and confirms clinical eligibility.

Days 5-7. Prior authorization submitted to commercial insurer with full documentation package. PA decisions on specialty drugs are required within 3 business days under Kentucky's managed care organization regulations. [15]

Days 7-10. PA approved (or peer-to-peer scheduled if denied). Prescription sent to specialty pharmacy.

Days 10-21. Specialty pharmacy ships inclisiran to the designated injection site.

Day 21 or sooner. First injection administered at prescriber's office or affiliated infusion center. Second injection scheduled for 90 days later. Third and all subsequent injections at 6-month intervals.

Total time from initial consult to first injection averages 3-6 weeks when commercial insurance approves on first submission. Appeals extend the timeline by 2-4 additional weeks in most cases. Patients on Medicaid pursuing PAP enrollment should budget 4-8 weeks given the additional income verification requirements.

Monitoring After Starting Leqvio in Kentucky

After the first injection, the FDA label requires no specific lab monitoring for inclisiran beyond what is clinically indicated. [2] The ORION trials did not identify a need for routine LFT monitoring after baseline. [3]

Most Kentucky clinicians and the ACC/AHA guideline recommend obtaining a repeat fasting lipid panel approximately 4-12 weeks after the second injection (Day 90) to confirm the therapeutic LDL-C response before the 6-month dose. [4] This response confirmation lipid panel also serves as the documentation required for PA reauthorization in most Kentucky commercial plans.

Injection site reactions (bruising, redness, or mild pain at the subcutaneous injection site) occurred in 2.6% of inclisiran patients vs. 1.8% placebo in the pooled ORION-10/11 analysis. [3] No cases of systemic hypersensitivity requiring discontinuation were reported. Patients should be counseled that injection site reactions are typically mild and self-limited.

The FDA Adverse Event Reporting System (FAERS) data through Q1 2025 show no new post-marketing safety signals for inclisiran beyond those described in the approved label. [2]

Obtain a repeat lipid panel at 4-12 weeks post-second-injection and document the LDL-C result in the chart before submitting the 12-month PA reauthorization.